OptimizeRx Corporation (OPRX)
NASDAQ: OPRX · Real-Time Price · USD
18.75
+1.15 (6.53%)
At close: Oct 3, 2025, 4:00 PM EDT
18.85
+0.10 (0.53%)
After-hours: Oct 3, 2025, 7:43 PM EDT

OptimizeRx Statistics

Total Valuation

OptimizeRx has a market cap or net worth of $348.09 million. The enterprise value is $360.48 million.

Market Cap348.09M
Enterprise Value 360.48M

Important Dates

The next estimated earnings date is Wednesday, November 12, 2025, after market close.

Earnings Date Nov 12, 2025
Ex-Dividend Date n/a

Share Statistics

OptimizeRx has 18.57 million shares outstanding. The number of shares has increased by 4.07% in one year.

Current Share Class 18.57M
Shares Outstanding 18.57M
Shares Change (YoY) +4.07%
Shares Change (QoQ) +2.95%
Owned by Insiders (%) 14.75%
Owned by Institutions (%) 65.11%
Float 14.32M

Valuation Ratios

PE Ratio n/a
Forward PE 35.79
PS Ratio 3.30
Forward PS 3.19
PB Ratio 2.92
P/TBV Ratio 70.71
P/FCF Ratio 33.66
P/OCF Ratio 33.43
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 45.28, with an EV/FCF ratio of 34.86.

EV / Earnings n/a
EV / Sales 3.44
EV / EBITDA 45.28
EV / EBIT 99.14
EV / FCF 34.86

Financial Position

The company has a current ratio of 2.57, with a Debt / Equity ratio of 0.24.

Current Ratio 2.57
Quick Ratio 2.41
Debt / Equity 0.24
Debt / EBITDA 3.53
Debt / FCF 2.80
Interest Coverage 0.61

Financial Efficiency

Return on equity (ROE) is -8.21% and return on invested capital (ROIC) is 1.49%.

Return on Equity (ROE) -8.21%
Return on Assets (ROA) 1.33%
Return on Invested Capital (ROIC) 1.49%
Return on Capital Employed (ROCE) 2.45%
Revenue Per Employee $812,000
Profits Per Employee -$76,504
Employee Count129
Asset Turnover 0.61
Inventory Turnover n/a

Taxes

In the past 12 months, OptimizeRx has paid $565,000 in taxes.

Income Tax 565,000
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +147.04% in the last 52 weeks. The beta is 1.25, so OptimizeRx's price volatility has been higher than the market average.

Beta (5Y) 1.25
52-Week Price Change +147.04%
50-Day Moving Average 16.87
200-Day Moving Average 10.85
Relative Strength Index (RSI) 52.93
Average Volume (20 Days) 379,530

Short Selling Information

The latest short interest is 1.73 million, so 9.33% of the outstanding shares have been sold short.

Short Interest 1.73M
Short Previous Month 1.35M
Short % of Shares Out 9.33%
Short % of Float 12.09%
Short Ratio (days to cover) 4.72

Income Statement

In the last 12 months, OptimizeRx had revenue of $104.75 million and -$9.87 million in losses. Loss per share was -$0.54.

Revenue104.75M
Gross Profit 67.45M
Operating Income 3.64M
Pretax Income -9.30M
Net Income -9.87M
EBITDA 7.96M
EBIT 3.64M
Loss Per Share -$0.54
Full Income Statement

Balance Sheet

The company has $16.59 million in cash and $28.98 million in debt, giving a net cash position of -$12.39 million or -$0.67 per share.

Cash & Cash Equivalents 16.59M
Total Debt 28.98M
Net Cash -12.39M
Net Cash Per Share -$0.67
Equity (Book Value) 119.28M
Book Value Per Share 6.43
Working Capital 33.02M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $10.41 million and capital expenditures -$72,000, giving a free cash flow of $10.34 million.

Operating Cash Flow 10.41M
Capital Expenditures -72,000
Free Cash Flow 10.34M
FCF Per Share $0.56
Full Cash Flow Statement

Margins

Gross margin is 64.39%, with operating and profit margins of 3.47% and -9.42%.

Gross Margin 64.39%
Operating Margin 3.47%
Pretax Margin -8.88%
Profit Margin -9.42%
EBITDA Margin 7.60%
EBIT Margin 3.47%
FCF Margin 9.87%

Dividends & Yields

OptimizeRx does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -4.07%
Shareholder Yield -4.07%
Earnings Yield -2.84%
FCF Yield 2.97%

Analyst Forecast

The average price target for OptimizeRx is $11.81, which is -37.01% lower than the current price. The consensus rating is "Buy".

Price Target $11.81
Price Target Difference -37.01%
Analyst Consensus Buy
Analyst Count 8
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

The last stock split was on May 14, 2018. It was a reverse split with a ratio of 1:3.

Last Split Date May 14, 2018
Split Type Reverse
Split Ratio 1:3

Scores

OptimizeRx has an Altman Z-Score of 1.96 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 1.96
Piotroski F-Score 6